D
38
-2
LLY
48
-3
EMC
71
-6
SHW
55
-3
UNP
43
3
EQR
42
-3
NWS
60
-2
VFC
53
-6
FITB
46
-2
SCHW
64
3
KR
56
11
PRGO
32
-3
AME
59
-3
VMC
48
-3
NRG
37
-7
DHR
39
-6
NVDA
51
-3
GME
57
-3
DE
56
-2
FTI
69
-2
D
38
-2
LLY
48
-3
EMC
71
-6
SHW
55
-3
UNP
43
3
EQR
42
-3
NWS
60
-2
VFC
53
-6
FITB
46
-2
SCHW
64
3
KR
56
11
PRGO
32
-3
AME
59
-3
VMC
48
-3
NRG
37
-7
DHR
39
-6
NVDA
51
-3
GME
57
-3
DE
56
-2
FTI
69
-2
Financhill
Back

Y-mAbs Therapeutics 10K Form

Sell
29

YMAB
Y-mAbs Therapeutics

Last Price:
10.01
Seasonality Move:
12.09%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive YMAB News And Ratings

See the #1 stock for the next 7 days that we like better than YMAB

YMAB Financial Statistics

Sales & Book Value

Annual Sales: $84.82M
Cash Flow: $-10.67M
Price / Cash Flow: 0
Annual Sales: $2.06
Price / Book: 4.98

Profitability

EPS (TTM): -0.54000
Net Income (TTM): $-23.86M
Gross Margin: $73.4M
Return on Equity: -24.45%
Return on Assets: -18.5%

Y-mAbs Therapeutics Earnings Forecast

Key Y-mAbs Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 5 years for YMAB is 86.54%.
  • The Selling, General & Administrative Expenses for YMAB have been equal to 52.88% of Gross Profit Margin.
  • The Research & Development expenses have been 63.92% of Revenue.
  • The Interest Expense is -0.79% of Operating Income.
  • The Net Earning history of YMAB is -25.26% of Total Revenues.
  • Per Share Earnings over the last 8 years have been positive in 2 years.

Y-mAbs Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: YMAB
CUSIP: 984241
Website: ymabs.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 3.92
Quick Ratio: 3.48

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

YMAB Technical Analysis vs Fundamental Analysis

Sell
29
Y-mAbs Therapeutics (YMAB) is a Sell

Is Y-mAbs Therapeutics a Buy or a Sell?